Vor Biopharma Inc.

NASDAQ: VOR · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexCIK 0001817229Reports USD

#1 of 1,417 Healthcare companies by revenue

EA Score

——

FH 41DQ —GM —SS 54

v0.1 · 35/100 weight · pillars only

↑ market scale, Altman-Z · ↓ listing tenure, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$696.0M

Employees

as of 2026-08-14

Market cap

$1.3B

as of 2026-08-14

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$696.0M-$696.0M2025

Operating income-$371.6M-$371.6M2025

Total assets$464.1M$464.1M2025

Liabilities$628.4M$628.4M2025

Equity-$164.3M-$164.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Vor Biopharma Inc.’s financial profile?

Vor Biopharma Inc. earned -$696.0M in FY2025 net income.

Peers · Healthcare

ORIC Pharmaceuticals, Inc.——LB Pharmaceuticals Inc Common Stock——Avalyn Pharma Inc. Common Stock——Aktis Oncology, Inc.——Corvus Pharmaceuticals, Inc.——Latigo Biotherapeutics Inc.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B48D

Key facts

CEOJean-Paul Kress

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeNASDAQ: VOR

Employees76

IPO date2021-02-05

Latest filings

10-Q2026-08-11 8-K2026-07-07 8-K2026-06-12 8-K2026-06-08 10-Q2026-05-13 DEF 14A2026-04-27 10-K2026-03-30 8-K2026-03-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.